On February 15, 2007 Senator Patrick Leahy, (D-Vt.) announced:
The Senate Judiciary Committee today passed a bill that takes aim at the growing problem of brand-name drug manufacturers using pay-off agreements to delay the public’s access to generic medicines. The bipartisan Preserve Access to Affordable Generics Act (S. 316) would prohibit brand-name drug companies from exploiting a loophole in the Hatch-Waxman Act to pay generic drug companies to delay entry of new generic medicines into the market.
Senator Leahy's statement read, in part:
In the weeks since introduction we have worked diligently with industry leaders to reach a proposal that lessens some of their concerns but that saves for our bottom line -- to end the trend of anti-competitive agreements between brand name pharmaceutical companies and generic companies to delay entry of affordable generics into the market. I am pleased that so many key players have come to the table in a good faith effort to find the middle ground.
More here.
Comments